The Myeloma Risk Variant of TNFRSF13B Shows Reduced NF-κB Signalling Activity in HEK293 Cells.

Richard Muyan Chen, Jackie L Ludgate, Robert J Weeks, Heather E Cunliffe, Ali G Dohan, Ian M Morison

Abstract read

In one paragraph

Article in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Richard Muyan ChenDepartment of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.ORCID https://orcid.org/0009-0001-9320-1877

Jackie L LudgateDepartment of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.

Robert J WeeksDepartment of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.

Heather E CunliffeDepartment of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.

Ali G DohanDepartment of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.ORCID https://orcid.org/0009-0003-8873-9423

Ian M MorisonDepartment of Pathology and Molecular Medicine, University of Otago, Dunedin, New Zealand.ORCID https://orcid.org/0000-0003-3616-0025

Funding

Cancer Research Trust New ZealandRichdale Trust

6 · The paper itself

Abstract

A single nucleotide variant rs34562254 in TNFRSF13B, which encodes TACI (transmembrane activator and CAML interactor), is associated with an increased risk of myeloma and MGUS. This variant encodes a proline to leucine substitution at residue 251 in the long isoform (P251L) and residue 205 in the short isoform (P205L) of TACI. Using HEK293 cells, NF-κB signalling of the variant and wild type forms of TACI was measured by using an NF-κB-luciferase reporter assay and by quantifying NF-κB p65 subcellular localisation. The TACI P205L variant showed substantially reduced NF-κB activity compared to the wild type version of the short isoform. This result suggests an indirect effect of TACI P205L on the increased risk of myeloma.

Indexed as

Multiple MyelomaNF-kappa BSignal TransductionTransmembrane Activator and CAML Interactor ProteinHEK293 CellsHumansPolymorphism, Single NucleotideProtein IsoformsTranscription Factor RelANF-kappa BProtein IsoformsTNFRSF13B protein, humanTranscription Factor RelATransmembrane Activator and CAML Interactor ProteinHEK293 cellsmyelomaNF‐κBTACITNFRSF13B

Identifiers

PMID42548249

DOI10.1111/ejh.70283

PMCPMC13643610

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.